Navigation Links
Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
Date:4/3/2008

nts who are under 18 years of

age.

For Full Prescribing Information on FOSRENOL, please visit http://www.fosrenol.com.

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI), and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger, and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's Web site: http://www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward- looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development including, but not limited to the successful development of JUVISTA(R) (Human TGF.3) and veleglucerase alfa (GA-GCB); manufacturing and commercialization including, but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder
'/>"/>

SOURCE Shire Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Orqis(R) Medicals Cancion(R) System Significantly Increases Cardiac Performance
2. New Data Shows Ranexa(R) Increases Glucose-Stimulated Insulin Secretion
3. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
4. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
5. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
6. Bone Mineral Content Continues to Increase in Obese Adolescents During Weight Loss
7. Study Linking Increased Risk of Death to Severe Psoriasis a Call to Action
8. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
9. FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis
10. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
11. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)...ard-winning video clips feature children, parents ... studies, BETHESDA, Md., Oct. 6 /PRNewswire-USNew...cines, research in children saves lives and improv...m the National Institutes of,Health (NIH), "Childr...linicalStudies.nhlbi.nih.gov ), offers parents and...
(Date:10/6/2008)...ata from SONIC Trial Showed REMICADE Therapy is Mo...ucosal Healing Compared with Standard ...la., Oct. 6 /- Data presented for the...th Crohn,s Disease Naive to,Immunomodulators and B...nto,the approach to care of patients with moderate...
(Date:10/6/2008)... - Conference Call Scheduled for 9:00 AM E... -- Dendreon Corporation (Nasdaq:,DNDN) announced ...alysis of,the Phase 3, randomized, double-blind, p...te AdenoCarcinoma Treatment, also known as D9902B)...efficacy of the,investigational active cellular im...
(Date:10/6/2008)...esign Concept of Other Product - Company,s Bioabso...posium, HONG KONG, Oct. 6 /- Data fr...ro-healing stent, OrbusNeich,s Genous Bio-engineer...nscatheter Cardiovascular,Therapeutics symposium, ... M.D., Ph.D., of the Academic Medical Center in,Am...
Breaking Medicine Technology:Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 2Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 3Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 2New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 5New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 6New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 7New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 8Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 2Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 3Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 4Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 2Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 3BD to Present at the Leerink Swann Molecular Diagnostics Roundtable Conference 15186 1Mens Health Guide for Ages 40 60 Launched by NHS Choices 15182 1Researchers urge ethics guidelines for human genome research 15179 1Researchers urge ethics guidelines for human genome research 15179 2AT 26T Announces Grant to Center on Aging University of Miami Miller School of Medicine 15177 1AT 26T Announces Grant to Center on Aging University of Miami Miller School of Medicine 15177 2AT 26T Announces Grant to Center on Aging University of Miami Miller School of Medicine 15177 3
(Date:10/6/2008)...childhood obesity, researcher notes , ,...s of middle schools have vending machines where sn...s. , The research demonstrates that there are v...those vending machines don,t always have the healt...istered dietitian with the Center for Obesity Rese...
(Date:10/6/2008)...Call/ -- HealthSouth,Corporation (NYSE: HLS ) tod...zed investor meeting in New York City. Presentatio...T at the Grand Hyatt New York, located at,109 E. 4..., 8:00 a.m. Continental Breakfast 8:30 a.m. ...r -- HealthSouth Overview and Industr...
(Date:10/6/2008)...eir family members can take,anonymous online, tele... 6 /PRNewswire-USNewswire/ -- Military life can pr...lies that are unique and,difficult. Some are manag...,worse and one problem can trigger other more seri...gs out to see what is really happening., (Photo: ...
(Date:10/6/2008)... of California, San Diego School of Medicine sugge...s production of a protective chemical normally fou...ns that are a common result of atopic dermatitis, ... by Richard Gallo, M.D., Ph.D., professor of medic...e UCSD School of Medicine and the Dermatology sect...
Breaking Medicine News(10 mins):Health News:Vending Machines Found in Most Middle Schools 2Health News:HealthSouth to Hold Investor Meeting November 10, 2008 2Health News:Many Military Installations Worldwide Participate in National Depression Screening Day 2Health News:Many Military Installations Worldwide Participate in National Depression Screening Day 3Health News:Oral vitamin D may help prevent some skin infections 2
...c'? No, its not another eating disorder, it's just...Professor Bruce Davies, of the University of Glamo... same problems as faced by people suffering from a...ncreasingly resorting to steroids and prescription...
...the Bombay High Court today raised the issue of sp...irected to take steps to curb the trade of such dr...ernment to file a reply in this regard by July 12....at Raj Mehta, who lost his son due to administrati...
...udents in New Zealand report low levels of perceiv...as a result, according to a new survey//. The Yout...Regional Public Health Service and Auckland Univer...nts about their mental and physical health, beside...
...ic surgery, most people want reduction of fat in a...hich involves a procedure wherein the body fat is ...uction is one of the most popular cosmetic surgery...nique are used to liquefy the fat and suck it out....
Other Medicine News:Health News:Indian Students in New Zealand Feel Insecure 2
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
Medicine Products: